Menopause is associated with declining estrogen levels and various symptoms that may affect women's quality of life. Interleukin-6 (IL-6), a pro-inflammatory cytokine influenced by estrogen, may serve as a potential biomarker for assessing the severity of menopausal symptoms. This study aimed to compare median serum IL-6 levels between postmenopausal and reproductive-age women and examine their differences according to the severity and types of menopausal symptoms. This analytical cross-sectional study involved 80 participants, comprising 40 postmenopausal women and 40 reproductive-age women. Participants completed the Menopause Rating Scale (MRS) questionnaire, and 3 mL of venous blood was collected to measure serum IL-6 levels at Prodia Clinic Laboratory. Data were analyzed using SPSS version 17 with ANOVA or the Kruskal–Wallis test, as appropriate. The median serum IL-6 level was higher in postmenopausal women than in reproductive-age women (1.70 vs. 1.37 pg/mL), although the difference was not statistically significant (p = 0.481). However, IL-6 levels differed significantly across the severity categories of menopausal symptoms (p < 0.0001), while no significant differences were found among the types of menopausal symptoms (p = 0.088). In conclusion, serum IL-6 levels did not differ significantly between postmenopausal and reproductive-age women but varied significantly according to the severity of menopausal symptoms. Further research is needed to clarify the potential role of IL-6 as a biomarker of menopausal symptom severity.
Copyrights © 2026